(Q38212169)

31 August 2017

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (English)

1 reference

31 August 2017

1 reference

1 reference

1 reference

4

Ruth March

1 reference

31 August 2017

David Cook

1

1 reference

31 August 2017

Dearg Brown

2

1 reference

31 August 2017

Robert Alexander

3

1 reference

31 August 2017

Paul Morgan

5

1 reference

31 August 2017

Gemma Satterthwaite

6

1 reference

31 August 2017

Menelas N Pangalos

7

1 reference

31 August 2017

language of work or name

1 reference

16 May 2014

1 reference

Nature Reviews Drug Discovery

31 August 2017

1 reference

31 August 2017

13

1 reference

31 August 2017

6

1 reference

31 August 2017

419-431

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4309

31 August 2017

0 references

cites work

The productivity crisis in pharmaceutical R&D.

1 reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

Lessons from 60 years of pharmaceutical innovation

31 March 2020

1 reference

Diagnosing the decline in pharmaceutical R&D efficiency

31 March 2020

1 reference

The industrialization of drug discovery

31 March 2020

1 reference

Clinical attrition due to biased preclinical assessments of potential efficacy.

31 March 2020

1 reference

Does size matter in R&D productivity? If not, what does?

31 March 2020

1 reference

Trial watch: phase II and phase III attrition rates 2011-2012.

31 March 2020

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

In-vitro assessment of platelet function

31 March 2020

1 reference

Genomic responses in mouse models poorly mimic human inflammatory diseases

31 March 2020

1 reference

Of mice and humans: are they the same?--Implications in cancer translational research

31 March 2020

1 reference

The translatability of animal models for clinical development: biomarkers and disease models

31 March 2020

1 reference

The benefits and limitations of animal models for translational research in neurodegenerative diseases

31 March 2020

1 reference

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

31 March 2020

1 reference

Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis

31 March 2020

1 reference

Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.

31 March 2020

1 reference

A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats

31 March 2020

1 reference

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

31 March 2020

1 reference

CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.

31 March 2020

1 reference

Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

Assessing the translatability of drug projects: what needs to be scored to predict success?

31 March 2020

1 reference

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

31 March 2020

1 reference

Antidepressant effects of ketamine in depressed patients

31 March 2020

1 reference

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

31 March 2020

1 reference

Glutamate-based antidepressants: 20 years on.

31 March 2020

1 reference

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

31 March 2020

1 reference

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

31 March 2020

1 reference

Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

31 March 2020

1 reference

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats

31 March 2020

1 reference

Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.

31 March 2020

1 reference

31 March 2020

1 reference

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

31 March 2020

1 reference

The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs

31 March 2020

1 reference

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

31 March 2020

1 reference

Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo

31 March 2020

1 reference

Market withdrawal of new molecular entities approved in the United States from 1980 to 2009

31 March 2020

1 reference

Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant

31 March 2020

1 reference

Drug-mediated toxicity: illuminating the 'bad' in the test tube by means of cellular assays?

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

Apolipoprotein E polymorphism and Alzheimer's disease.

31 March 2020

1 reference

Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?

31 March 2020

1 reference

Microarray-based identification of novel biomarkers in asthma

31 March 2020

1 reference

IL-13: a promising therapeutic target for bronchial asthma.

31 March 2020

1 reference

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

31 March 2020

1 reference

Lebrikizumab treatment in adults with asthma

31 March 2020

1 reference

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

31 March 2020

1 reference

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

31 March 2020

1 reference

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

31 March 2020

1 reference

Model-based drug discovery: implementation and impact.

31 March 2020

1 reference

The sequence of events that underlie quantal transmission at central glutamatergic synapses

31 March 2020

1 reference

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment

31 March 2020

1 reference

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

31 March 2020

1 reference

Prostaglandin D2 as a mediator of allergic asthma

31 March 2020

1 reference

A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep.

31 March 2020

1 reference

CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation.

31 March 2020

1 reference

Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

31 March 2020

1 reference

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients

31 March 2020

1 reference

5th conference clinical trials on Alzheimer's disease: October 29-31, 2012, Grimaldi Forum, Convention Center, Monte Carlo

31 March 2020

1 reference

12 December 2020

[Clarification of the pathogenesis and development of clinical examination for allergic diseases]

1 reference

12 December 2020

Lebrikizumab in the personalized management of asthma

1 reference

12 December 2020

Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block.

1 reference

12 December 2020

In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

1 reference

12 December 2020

Evidence for ordering of Alzheimer disease biomarkers

1 reference

12 December 2020

Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751.

1 reference

12 December 2020

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4309

1 reference

31 August 2017

1 reference